Skip to main content
Erschienen in: Advances in Therapy 2/2014

01.02.2014 | Review

Opioid-Induced Endocrinopathy in Cancer Patients: An Underestimated Clinical Problem

verfasst von: Tomasz Buss, Wojciech Leppert

Erschienen in: Advances in Therapy | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The impact of both endogenous and exogenous opioids on the endocrine system has been known for many years. With the increased use of opioids in chronic pain treatment, the research focuses mainly on their effects on the endocrine system in patients with chronic non-malignant pain. Despite the wide dissemination of cancer, there has been little research on the possible effects of opioids on the endocrine system in cancer patients. For the growing number of cancer survivors and patients in long-term remission who take opioids, other aspects of endocrine disorders caused or exacerbated by opioids will have practical and clinical importance. Conversely, this problem may be less relevant for patients in active cancer treatment or in the advanced stage of disease. This article presents the available research on the effects of opioids on the endocrine system and the clinical consequences resulting from opioid use in cancer patients. Clinicians who use opioids in clinical practice should be aware of the existence of the endocrine symptoms of opioid therapy. There is still a need for more research in this area to maintain the best possible quality of life for cancer patients treated with opioid analgesics.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65:1257–317.PubMedCrossRef Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65:1257–317.PubMedCrossRef
2.
3.
Zurück zum Zitat Grossman A. Brain opiates and neuroendocrine function. Clin Endocrinol Metab. 1983;12:725–46.PubMedCrossRef Grossman A. Brain opiates and neuroendocrine function. Clin Endocrinol Metab. 1983;12:725–46.PubMedCrossRef
4.
Zurück zum Zitat Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31:98–132.PubMedCrossRef Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31:98–132.PubMedCrossRef
5.
Zurück zum Zitat Delitala G, Tomasi PA, Palermo M, Ross RJ, Grossman A, Besser GM. Opioids stimulate growth hormone (GH) release in man independently of GH-releasing hormone. J Clin Endocrinol Metab. 1989;69:356–8.PubMedCrossRef Delitala G, Tomasi PA, Palermo M, Ross RJ, Grossman A, Besser GM. Opioids stimulate growth hormone (GH) release in man independently of GH-releasing hormone. J Clin Endocrinol Metab. 1989;69:356–8.PubMedCrossRef
6.
7.
Zurück zum Zitat Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–22.PubMedCrossRef Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85:2215–22.PubMedCrossRef
8.
Zurück zum Zitat Merza Z, Edwards N, Walters SJ, Newell-Price J, Ross RJ. Patients with chronic pain and abnormal pituitary function require investigation. Lancet. 2003;361:2203–4.PubMedCrossRef Merza Z, Edwards N, Walters SJ, Newell-Price J, Ross RJ. Patients with chronic pain and abnormal pituitary function require investigation. Lancet. 2003;361:2203–4.PubMedCrossRef
9.
Zurück zum Zitat Bhansali A, Velayutham P, Sialy R, Sethi B. Effect of opiates on growth hormone secretion in acromegaly. Horm Metab Res. 2005;37:425–7.PubMedCrossRef Bhansali A, Velayutham P, Sialy R, Sethi B. Effect of opiates on growth hormone secretion in acromegaly. Horm Metab Res. 2005;37:425–7.PubMedCrossRef
10.
Zurück zum Zitat Pugliese MT, Abdenur J, Fort P, Lifshitz F. The relationship between beta-endorphin and the growth hormone (GH) response to GH releasing hormone in prepubertal children. Endocr Res. 1992;18:41–50.PubMed Pugliese MT, Abdenur J, Fort P, Lifshitz F. The relationship between beta-endorphin and the growth hormone (GH) response to GH releasing hormone in prepubertal children. Endocr Res. 1992;18:41–50.PubMed
11.
Zurück zum Zitat Delitala G, Grossman A, Besser GM. The participation of hypothalamic dopamine in morphine-induced prolactin release in man. Clin Endocrinol (Oxf). 1983;19:437–44.PubMedCrossRef Delitala G, Grossman A, Besser GM. The participation of hypothalamic dopamine in morphine-induced prolactin release in man. Clin Endocrinol (Oxf). 1983;19:437–44.PubMedCrossRef
12.
Zurück zum Zitat Hemmings R, Fox G, Tolis G. Effect of morphine on the hypothalamic-pituitary axis in postmenopausal women. Fertil Steril. 1982;37:389–91.PubMed Hemmings R, Fox G, Tolis G. Effect of morphine on the hypothalamic-pituitary axis in postmenopausal women. Fertil Steril. 1982;37:389–91.PubMed
13.
Zurück zum Zitat Ragni G, De Lauretis L, Bestetti O, Sghedoni D, Gambaro V. Gonadal function in male heroin and methadone addicts. Int J Androl. 1988;11:93–100.PubMedCrossRef Ragni G, De Lauretis L, Bestetti O, Sghedoni D, Gambaro V. Gonadal function in male heroin and methadone addicts. Int J Androl. 1988;11:93–100.PubMedCrossRef
14.
Zurück zum Zitat Moshtaghi-Kashanian GR, Esmaeeli F, Dabiri S. Enhanced prolactin levels in opium smokers. Addict Biol. 2005;10:345–9.PubMedCrossRef Moshtaghi-Kashanian GR, Esmaeeli F, Dabiri S. Enhanced prolactin levels in opium smokers. Addict Biol. 2005;10:345–9.PubMedCrossRef
15.
Zurück zum Zitat Howlett TA, Rees LH. Endogenous opioid peptides and hypothalamo-pituitary function. Annu Rev Physiol. 1986;48:527–36.PubMedCrossRef Howlett TA, Rees LH. Endogenous opioid peptides and hypothalamo-pituitary function. Annu Rev Physiol. 1986;48:527–36.PubMedCrossRef
16.
Zurück zum Zitat Steardo L, Monteleone P, Tamminga CA, et al. Differential responses in prolactin levels induced by naloxone in humans. Psychoneuroendocrinology. 1985;10:203–9.PubMedCrossRef Steardo L, Monteleone P, Tamminga CA, et al. Differential responses in prolactin levels induced by naloxone in humans. Psychoneuroendocrinology. 1985;10:203–9.PubMedCrossRef
17.
Zurück zum Zitat Amoroso S, Di Renzo G, Cuocolo R, et al. Evidence for a differential interaction of buprenorphine with opiate receptor subtypes controlling prolactin secretion. Eur J Pharmacol. 1988;145:257–60.PubMedCrossRef Amoroso S, Di Renzo G, Cuocolo R, et al. Evidence for a differential interaction of buprenorphine with opiate receptor subtypes controlling prolactin secretion. Eur J Pharmacol. 1988;145:257–60.PubMedCrossRef
18.
Zurück zum Zitat Devilla L, Pende A, Morgano A, Giusti M, Musso NR, Lotti G. Morphine-induced TSH release in normal and hypothyroid subjects. Neuroendocrinology. 1985;40:303–8.PubMedCrossRef Devilla L, Pende A, Morgano A, Giusti M, Musso NR, Lotti G. Morphine-induced TSH release in normal and hypothyroid subjects. Neuroendocrinology. 1985;40:303–8.PubMedCrossRef
19.
Zurück zum Zitat Ogrin C, Schussler GC. Suppression of thyrotropin by morphine in a severely stressed patient. Endocr J. 2005;52:265–9.PubMedCrossRef Ogrin C, Schussler GC. Suppression of thyrotropin by morphine in a severely stressed patient. Endocr J. 2005;52:265–9.PubMedCrossRef
20.
Zurück zum Zitat Grossman A, West S, Williams J, Evans J, Rees LH, Besser GM. The role of opiate peptides in the control of prolactin in the puerperium, and TSH in primary hypothyroidism. Clin Endocrinol (Oxf). 1982;16:317–20.PubMedCrossRef Grossman A, West S, Williams J, Evans J, Rees LH, Besser GM. The role of opiate peptides in the control of prolactin in the puerperium, and TSH in primary hypothyroidism. Clin Endocrinol (Oxf). 1982;16:317–20.PubMedCrossRef
21.
Zurück zum Zitat Rauhala P, Tuominen RK, Männistö PT. Opiate receptor subtypes in the regulation of thyrotropin and prolactin secretion in the rat. Horm Res. 1988;29:218–22.PubMedCrossRef Rauhala P, Tuominen RK, Männistö PT. Opiate receptor subtypes in the regulation of thyrotropin and prolactin secretion in the rat. Horm Res. 1988;29:218–22.PubMedCrossRef
22.
Zurück zum Zitat Freire-Garabal M, Balboa JL, Núñez MJ, Castaño MT, Belmonte A. Autoradiographic evidence of opioid binding sites in the thyroid gland. Horm Metab Res. 1992;24:494–5.PubMedCrossRef Freire-Garabal M, Balboa JL, Núñez MJ, Castaño MT, Belmonte A. Autoradiographic evidence of opioid binding sites in the thyroid gland. Horm Metab Res. 1992;24:494–5.PubMedCrossRef
23.
Zurück zum Zitat Rittmaster RS, Cutler GB, Sobel DO, et al. Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects. J Clin Endocrinol Metab. 1985;60:891–5.PubMedCrossRef Rittmaster RS, Cutler GB, Sobel DO, et al. Morphine inhibits the pituitary-adrenal response to ovine corticotropin-releasing hormone in normal subjects. J Clin Endocrinol Metab. 1985;60:891–5.PubMedCrossRef
24.
Zurück zum Zitat Grossman A, Moult PJ, Cunnah D, Besser M. Different opioid mechanisms are involved in the modulation of ACTH and gonadotrophin release in man. Neuroendocrinology. 1986;42:357–60.PubMedCrossRef Grossman A, Moult PJ, Cunnah D, Besser M. Different opioid mechanisms are involved in the modulation of ACTH and gonadotrophin release in man. Neuroendocrinology. 1986;42:357–60.PubMedCrossRef
25.
Zurück zum Zitat Pfeiffer A, Knepel W, Braun S, Meyer HD, Lohmann H, Brantl V. Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man. Horm Metab Res. 1986;18:842–8.PubMedCrossRef Pfeiffer A, Knepel W, Braun S, Meyer HD, Lohmann H, Brantl V. Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man. Horm Metab Res. 1986;18:842–8.PubMedCrossRef
26.
Zurück zum Zitat Facchinetti F, Volpe A, Farci G, et al. Hypothalamus–pituitary–adrenal axis of heroin addicts. Drug Alcohol Depend. 1985;15:361–6.PubMedCrossRef Facchinetti F, Volpe A, Farci G, et al. Hypothalamus–pituitary–adrenal axis of heroin addicts. Drug Alcohol Depend. 1985;15:361–6.PubMedCrossRef
27.
Zurück zum Zitat Allolio B, Schulte HM, Deuss U, Kallabis D, Hamel E, Winkelman W. Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. Acta Endocrinol (Copenh). 1987;114:509–14.PubMed Allolio B, Schulte HM, Deuss U, Kallabis D, Hamel E, Winkelman W. Effect of oral morphine and naloxone on pituitary-adrenal response in man induced by human corticotropin-releasing hormone. Acta Endocrinol (Copenh). 1987;114:509–14.PubMed
28.
Zurück zum Zitat Oltmanns KM, Fehm HL, Peters A. Chronic fentanyl application induces adrenocortical insufficiency. J Intern Med. 2005;257:478–80.PubMedCrossRef Oltmanns KM, Fehm HL, Peters A. Chronic fentanyl application induces adrenocortical insufficiency. J Intern Med. 2005;257:478–80.PubMedCrossRef
29.
Zurück zum Zitat Müssig K, Knaus-Dittmann D, Schmidt H, Mörike K, Häring HU. Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment. Clin Endocrinol (Oxf). 2007;66:604–5.PubMed Müssig K, Knaus-Dittmann D, Schmidt H, Mörike K, Häring HU. Secondary adrenal failure and secondary amenorrhoea following hydromorphone treatment. Clin Endocrinol (Oxf). 2007;66:604–5.PubMed
30.
Zurück zum Zitat Pullan PT, Watson FE, Seow SS, Rappeport W. Methadone-induced hypoadrenalism. Lancet. 1983;1:714.PubMedCrossRef Pullan PT, Watson FE, Seow SS, Rappeport W. Methadone-induced hypoadrenalism. Lancet. 1983;1:714.PubMedCrossRef
31.
Zurück zum Zitat Fallo F, Boscaro M, Sonino N, Mantero F. Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism. J Endocrinol Invest. 1988;11:261–5.PubMed Fallo F, Boscaro M, Sonino N, Mantero F. Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism. J Endocrinol Invest. 1988;11:261–5.PubMed
32.
Zurück zum Zitat Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7:901–7.PubMedCrossRef Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid-induced inhibition of adrenal androgen production. J Pain. 2006;7:901–7.PubMedCrossRef
33.
Zurück zum Zitat Krazinski BE, Koziorowski M, Brzuzan P, Okrasa S. The expression of genes encoding opioid precursors and the influence of opioid receptor agonists on steroidogenesis in porcine adrenocortical cells in vitro. J Physiol Pharmacol. 2011;62:461–8.PubMed Krazinski BE, Koziorowski M, Brzuzan P, Okrasa S. The expression of genes encoding opioid precursors and the influence of opioid receptor agonists on steroidogenesis in porcine adrenocortical cells in vitro. J Physiol Pharmacol. 2011;62:461–8.PubMed
34.
Zurück zum Zitat Walter M, Gerber H, Kuhl HC, Schmid O, Joechle W, Lanz C, Brenneisen R, Schächinger H, Riecher-Rössler A, Wiesbeck GA, Borgwardt SJ. Acute effects of intravenous heroin on the hypothalamic-pituitary-adrenal axis response: a controlled trial. J Clin Psychopharmacol. 2013;33:193–8.PubMedCrossRef Walter M, Gerber H, Kuhl HC, Schmid O, Joechle W, Lanz C, Brenneisen R, Schächinger H, Riecher-Rössler A, Wiesbeck GA, Borgwardt SJ. Acute effects of intravenous heroin on the hypothalamic-pituitary-adrenal axis response: a controlled trial. J Clin Psychopharmacol. 2013;33:193–8.PubMedCrossRef
35.
Zurück zum Zitat Zhang GF, Ren YP, Sheng LX, et al. Dysfunction of the hypothalamic-pituitary-adrenal axis in opioid dependent subjects: effects of acute and protracted abstinence. Am J Drug Alcohol Abuse. 2008;34:760–8.PubMedCrossRef Zhang GF, Ren YP, Sheng LX, et al. Dysfunction of the hypothalamic-pituitary-adrenal axis in opioid dependent subjects: effects of acute and protracted abstinence. Am J Drug Alcohol Abuse. 2008;34:760–8.PubMedCrossRef
36.
Zurück zum Zitat Smith HS, Elliott JA. Opioid-induced androgen deficiency (OPIAD). Pain Physician. 2012;15:ES145–56.PubMed Smith HS, Elliott JA. Opioid-induced androgen deficiency (OPIAD). Pain Physician. 2012;15:ES145–56.PubMed
37.
Zurück zum Zitat De la Rosa RE, Hennessey JV. Hypogonadism and methadone: hypothalamic hypogonadism after long-term use of high-dose methadone. Endocr Pract. 1996;2:4–7.PubMedCrossRef De la Rosa RE, Hennessey JV. Hypogonadism and methadone: hypothalamic hypogonadism after long-term use of high-dose methadone. Endocr Pract. 1996;2:4–7.PubMedCrossRef
38.
Zurück zum Zitat Pende A, Musso NR, Montaldi ML, Pastorino G, Arzese M, Devilla L. Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. Biomed Pharmacother. 1986;40:178–82.PubMed Pende A, Musso NR, Montaldi ML, Pastorino G, Arzese M, Devilla L. Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. Biomed Pharmacother. 1986;40:178–82.PubMed
39.
Zurück zum Zitat Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009;117:38–43.PubMedCentralPubMedCrossRef Fraser LA, Morrison D, Morley-Forster P, et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009;117:38–43.PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Ahmed MI, Duleba AJ, El Shahat O, Ibrahim ME, Salem A. Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Hum Reprod. 2008;23:2564–9.PubMedCrossRef Ahmed MI, Duleba AJ, El Shahat O, Ibrahim ME, Salem A. Naltrexone treatment in clomiphene resistant women with polycystic ovary syndrome. Hum Reprod. 2008;23:2564–9.PubMedCrossRef
41.
Zurück zum Zitat Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36.PubMedCrossRef Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9:28–36.PubMedCrossRef
42.
Zurück zum Zitat Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–84.PubMedCrossRef Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. J Pain. 2002;3:377–84.PubMedCrossRef
43.
Zurück zum Zitat Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manag. 1994;9:126–31.CrossRef Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manag. 1994;9:126–31.CrossRef
44.
Zurück zum Zitat Fabbri A, Jannini EA, Gnessi L, et al. Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology. 1989;14:103–11.PubMedCrossRef Fabbri A, Jannini EA, Gnessi L, et al. Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology. 1989;14:103–11.PubMedCrossRef
45.
Zurück zum Zitat Skipworth RJ, Moses AG, Sangster K, et al. Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 2011;19:391–401.PubMedCrossRef Skipworth RJ, Moses AG, Sangster K, et al. Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 2011;19:391–401.PubMedCrossRef
46.
Zurück zum Zitat Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851–8.PubMedCrossRef Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851–8.PubMedCrossRef
47.
Zurück zum Zitat Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5:684–92.PubMedCrossRef Hallinan R, Byrne A, Agho K, McMahon C, Tynan P, Attia J. Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment. J Sex Med. 2008;5:684–92.PubMedCrossRef
48.
Zurück zum Zitat Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med. 2006;260:76–87.PubMedCrossRef Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med. 2006;260:76–87.PubMedCrossRef
49.
Zurück zum Zitat Carbone LD, Chin AS, Lee TA, et al. The association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord Med. 2013;36:91–6.PubMedCrossRef Carbone LD, Chin AS, Lee TA, et al. The association of opioid use with incident lower extremity fractures in spinal cord injury. J Spinal Cord Med. 2013;36:91–6.PubMedCrossRef
50.
Zurück zum Zitat Ensrud KE, Blackwell T, Mangione CM, Group SoOFR, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003;163:949–57.PubMedCrossRef Ensrud KE, Blackwell T, Mangione CM, Group SoOFR, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003;163:949–57.PubMedCrossRef
51.
Zurück zum Zitat Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005;118:1414.PubMedCrossRef Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH. Bone mineral density in subjects using central nervous system-active medications. Am J Med. 2005;118:1414.PubMedCrossRef
52.
Zurück zum Zitat Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000;16:251–4.PubMedCrossRef Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain. 2000;16:251–4.PubMedCrossRef
53.
Zurück zum Zitat Pérez-Castrillón JL, Olmos JM, Gómez JJ, et al. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology. 2000;72:187–94.PubMedCrossRef Pérez-Castrillón JL, Olmos JM, Gómez JJ, et al. Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells. Neuroendocrinology. 2000;72:187–94.PubMedCrossRef
54.
Zurück zum Zitat Rico H, Costales C, Cabranes JA, Escudero M. Lower serum osteocalcin levels in pregnant drug users and their newborns at the time of delivery. Obstet Gynecol. 1990;75:998–1000.PubMed Rico H, Costales C, Cabranes JA, Escudero M. Lower serum osteocalcin levels in pregnant drug users and their newborns at the time of delivery. Obstet Gynecol. 1990;75:998–1000.PubMed
55.
Zurück zum Zitat Chrastil J, Sampson C, Jones KB, Higgins TF. Postoperative opioid administration inhibits bone healing in an animal model. Clin Orthop Relat Res. 2013;471:4076–81.PubMedCrossRef Chrastil J, Sampson C, Jones KB, Higgins TF. Postoperative opioid administration inhibits bone healing in an animal model. Clin Orthop Relat Res. 2013;471:4076–81.PubMedCrossRef
56.
Zurück zum Zitat Boulton AJ, Wilson N, Turnbull KW, Yip RW. Haemodynamic and plasma vasopressin responses during high-dose fentanyl or sufentanil anaesthesia. Can Anaesth Soc J. 1986;33:475–83.PubMedCrossRef Boulton AJ, Wilson N, Turnbull KW, Yip RW. Haemodynamic and plasma vasopressin responses during high-dose fentanyl or sufentanil anaesthesia. Can Anaesth Soc J. 1986;33:475–83.PubMedCrossRef
57.
Zurück zum Zitat Weiskopf RB, Reid IA, Fisher DM, Holmes MA, Rosen JI, Keil LC. Effects of fentanyl on vasopressin secretion in human subjects. J Pharmacol Exp Ther. 1987;242:970–3.PubMed Weiskopf RB, Reid IA, Fisher DM, Holmes MA, Rosen JI, Keil LC. Effects of fentanyl on vasopressin secretion in human subjects. J Pharmacol Exp Ther. 1987;242:970–3.PubMed
58.
Zurück zum Zitat Van Wimersma Greidanus TB, Thody TJ, Verspaget H, et al. Effects of morphine and beta-endorphin on basal and elevated plasma levels of alpha-MSH and vasopressin. Life Sci. 1979;24:579–85.PubMedCrossRef Van Wimersma Greidanus TB, Thody TJ, Verspaget H, et al. Effects of morphine and beta-endorphin on basal and elevated plasma levels of alpha-MSH and vasopressin. Life Sci. 1979;24:579–85.PubMedCrossRef
59.
Zurück zum Zitat Bozkurt P, Kaya G, Yeker Y, et al. Effects of systemic and epidural morphine on antidiuretic hormone levels in children. Paediatr Anaesth. 2003;13:508–14.PubMedCrossRef Bozkurt P, Kaya G, Yeker Y, et al. Effects of systemic and epidural morphine on antidiuretic hormone levels in children. Paediatr Anaesth. 2003;13:508–14.PubMedCrossRef
60.
Zurück zum Zitat Awoke S, Voyles NR, Bhathena SJ, Tanenberg RJ, Recant L. Alterations of plasma opioid activity in human diabetics. Life Sci. 1984;34:1999–2006.PubMedCrossRef Awoke S, Voyles NR, Bhathena SJ, Tanenberg RJ, Recant L. Alterations of plasma opioid activity in human diabetics. Life Sci. 1984;34:1999–2006.PubMedCrossRef
61.
Zurück zum Zitat Leu J, Cui MH, Shamoon H, Gabriely I. Hypoglycemia-associated autonomic failure is prevented by opioid receptor blockade. J Clin Endocrinol Metab. 2009;94:3372–80.PubMedCrossRef Leu J, Cui MH, Shamoon H, Gabriely I. Hypoglycemia-associated autonomic failure is prevented by opioid receptor blockade. J Clin Endocrinol Metab. 2009;94:3372–80.PubMedCrossRef
62.
Zurück zum Zitat Giugliano D, Quatraro A, Consoli G, Ceriello A, Torella R, D’Onofrio F. Inhibitory effect of enkephalin on insulin secretion in healthy subjects and in non insulin-dependent diabetic subjects. Metabolism. 1987;36:286–9.PubMedCrossRef Giugliano D, Quatraro A, Consoli G, Ceriello A, Torella R, D’Onofrio F. Inhibitory effect of enkephalin on insulin secretion in healthy subjects and in non insulin-dependent diabetic subjects. Metabolism. 1987;36:286–9.PubMedCrossRef
63.
Zurück zum Zitat Giugliano D. Morphine, opioid peptides, and pancreatic islet function. Diabetes Care. 1984;7:92–8.PubMedCrossRef Giugliano D. Morphine, opioid peptides, and pancreatic islet function. Diabetes Care. 1984;7:92–8.PubMedCrossRef
64.
Zurück zum Zitat Brambilla F, Guerrini A, Guastalla A, Beretta P, Maio DD. Glucose-insulin metabolism in heroin addicts. Neuropsychobiology. 1976;2:341–9.PubMedCrossRef Brambilla F, Guerrini A, Guastalla A, Beretta P, Maio DD. Glucose-insulin metabolism in heroin addicts. Neuropsychobiology. 1976;2:341–9.PubMedCrossRef
65.
Zurück zum Zitat Sood A, Thakur V, Ahuja MM. Effect of chronic opioid administration on glycosylated haemoglobin levels in heroin addicts. Indian J Med Res. 1989;90:51–4.PubMed Sood A, Thakur V, Ahuja MM. Effect of chronic opioid administration on glycosylated haemoglobin levels in heroin addicts. Indian J Med Res. 1989;90:51–4.PubMed
66.
Zurück zum Zitat Li L, Setoguchi S, Cabral H, Jick S. Opioids and risk of type 2 diabetes in adults with non-cancer pain. Pain Physician. 2013;16:77–88.PubMed Li L, Setoguchi S, Cabral H, Jick S. Opioids and risk of type 2 diabetes in adults with non-cancer pain. Pain Physician. 2013;16:77–88.PubMed
67.
Zurück zum Zitat Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.PubMedCrossRef Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.PubMedCrossRef
68.
Zurück zum Zitat Shah P, Aniszweski J, Service FJ. Propoxyphene-induced hypoglycemia in renal failure. Endocr Pract. 2006;12:170–3.PubMedCrossRef Shah P, Aniszweski J, Service FJ. Propoxyphene-induced hypoglycemia in renal failure. Endocr Pract. 2006;12:170–3.PubMedCrossRef
69.
Zurück zum Zitat Moryl N, Pope J, Obbens E. Hypoglycemia during rapid methadone dose escalation. J Opioid Manag. 2013;9:29–34.PubMedCrossRef Moryl N, Pope J, Obbens E. Hypoglycemia during rapid methadone dose escalation. J Opioid Manag. 2013;9:29–34.PubMedCrossRef
70.
Zurück zum Zitat Karci A, Tasdogen A, Erkin Y, Aktaş G, Elar Z. The analgesic effect of morphine on postoperative pain in diabetic patients. Acta Anaesthesiol Scand. 2004;48:619–24.PubMedCrossRef Karci A, Tasdogen A, Erkin Y, Aktaş G, Elar Z. The analgesic effect of morphine on postoperative pain in diabetic patients. Acta Anaesthesiol Scand. 2004;48:619–24.PubMedCrossRef
71.
Zurück zum Zitat Bradley R, Javorsky M, Aron DC, Findling JW, Tyrrell JB. Greenspan’s basic and clinical endocrinology. Greenspan’s basic and clinical endocrinology. New York: McGraw-Hill Companies; 2011. Bradley R, Javorsky M, Aron DC, Findling JW, Tyrrell JB. Greenspan’s basic and clinical endocrinology. Greenspan’s basic and clinical endocrinology. New York: McGraw-Hill Companies; 2011.
72.
Zurück zum Zitat MacDonald N. Terminology in cancer cachexia: importance and status. Curr Opin Clin Nutr Metab Care. 2012;15:220–5.PubMedCrossRef MacDonald N. Terminology in cancer cachexia: importance and status. Curr Opin Clin Nutr Metab Care. 2012;15:220–5.PubMedCrossRef
73.
Zurück zum Zitat Matoushek TA, Kearney TC, Lindsay TJ, Herndon CM. Loss of antinociceptive effectiveness of morphine and oxycodone following titration of levothyroxine: case reports and a brief review of published literature. J Opioid Manag. 2012;8:193–8.PubMedCrossRef Matoushek TA, Kearney TC, Lindsay TJ, Herndon CM. Loss of antinociceptive effectiveness of morphine and oxycodone following titration of levothyroxine: case reports and a brief review of published literature. J Opioid Manag. 2012;8:193–8.PubMedCrossRef
74.
Zurück zum Zitat Bello G, Ceaichisciuc I, Silva S, Antonelli M. The role of thyroid dysfunction in the critically ill: a review of the literature. Minerva Anestesiol. 2010;76:919–28.PubMed Bello G, Ceaichisciuc I, Silva S, Antonelli M. The role of thyroid dysfunction in the critically ill: a review of the literature. Minerva Anestesiol. 2010;76:919–28.PubMed
75.
Zurück zum Zitat Ambrosi B, Bochicchio D, Faglia G. Loperamide, an opiate analogue, inhibits plasma ACTH levels in patients with Addison’s disease. Clin Endocrinol (Oxf). 1986;24:483–9.PubMedCrossRef Ambrosi B, Bochicchio D, Faglia G. Loperamide, an opiate analogue, inhibits plasma ACTH levels in patients with Addison’s disease. Clin Endocrinol (Oxf). 1986;24:483–9.PubMedCrossRef
76.
Zurück zum Zitat Auernhammer CJ, Stalla GK, Lange M, Pfeiffer A, Müller OA. Effects of loperamide on the human hypothalamo-pituitary-adrenal axis in vivo and in vitro. J Clin Endocrinol Metab. 1992;75:552–7.PubMed Auernhammer CJ, Stalla GK, Lange M, Pfeiffer A, Müller OA. Effects of loperamide on the human hypothalamo-pituitary-adrenal axis in vivo and in vitro. J Clin Endocrinol Metab. 1992;75:552–7.PubMed
77.
Zurück zum Zitat Thornton LM, Andersen BL, Blakely WP. The pain, depression, and fatigue symptom cluster in advanced breast cancer: covariation with the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Health Psychol. 2010;29:333–7.PubMedCentralPubMedCrossRef Thornton LM, Andersen BL, Blakely WP. The pain, depression, and fatigue symptom cluster in advanced breast cancer: covariation with the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Health Psychol. 2010;29:333–7.PubMedCentralPubMedCrossRef
78.
Zurück zum Zitat Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006;7:200–10.PubMedCrossRef Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain. 2006;7:200–10.PubMedCrossRef
79.
Zurück zum Zitat Lee CE, McArdle A, Griffiths RD. The role of hormones, cytokines and heat shock proteins during age-related muscle loss. Clin Nutr. 2007;26:524–34.PubMedCrossRef Lee CE, McArdle A, Griffiths RD. The role of hormones, cytokines and heat shock proteins during age-related muscle loss. Clin Nutr. 2007;26:524–34.PubMedCrossRef
80.
Zurück zum Zitat Garcia JM, Li H, Mann D, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106:2583–91.PubMedCrossRef Garcia JM, Li H, Mann D, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106:2583–91.PubMedCrossRef
81.
Zurück zum Zitat Berent-Spillson A, Love T, Pop-Busui R, et al. Insulin resistance influences central opioid activity in polycystic ovary syndrome. Fertil Steril. 2011;95:2494–8.PubMedCentralPubMedCrossRef Berent-Spillson A, Love T, Pop-Busui R, et al. Insulin resistance influences central opioid activity in polycystic ovary syndrome. Fertil Steril. 2011;95:2494–8.PubMedCentralPubMedCrossRef
82.
Zurück zum Zitat Ferenczi S, Nunez C, Pinter-Kubler B, et al. Changes in metabolic-related variables during chronic morphine treatment. Neurochem Internat. 2010;57:223–30.CrossRef Ferenczi S, Nunez C, Pinter-Kubler B, et al. Changes in metabolic-related variables during chronic morphine treatment. Neurochem Internat. 2010;57:223–30.CrossRef
83.
Zurück zum Zitat Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014;132:236–40. Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014;132:236–40.
84.
Zurück zum Zitat Azoulay D, Jacobs JM, Cialic R, Mor EE, Stessman J. Opioids, survival, and advanced cancer in the hospice setting. J Am Med Dir Assoc. 2011;12:129–34.PubMedCrossRef Azoulay D, Jacobs JM, Cialic R, Mor EE, Stessman J. Opioids, survival, and advanced cancer in the hospice setting. J Am Med Dir Assoc. 2011;12:129–34.PubMedCrossRef
85.
Zurück zum Zitat Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25:170–5.PubMedCrossRef Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25:170–5.PubMedCrossRef
Metadaten
Titel
Opioid-Induced Endocrinopathy in Cancer Patients: An Underestimated Clinical Problem
verfasst von
Tomasz Buss
Wojciech Leppert
Publikationsdatum
01.02.2014
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 2/2014
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-014-0096-x

Weitere Artikel der Ausgabe 2/2014

Advances in Therapy 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.